Omeros (NASDAQ:OMER) Issues Earnings Results

Omeros (NASDAQ:OMER) issued its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.17, RTT News reports. During the same quarter in the previous year, the company posted ($0.15) EPS.

Omeros Stock Down 3.0 %

OMER opened at $8.22 on Tuesday. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60. The firm has a 50-day simple moving average of $8.66 and a two-hundred day simple moving average of $7.58. The company has a market capitalization of $476.35 million, a PE ratio of -3.56 and a beta of 2.03.

Analysts Set New Price Targets

A number of research analysts recently weighed in on OMER shares. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research note on Friday, January 17th. D. Boral Capital restated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research report on Tuesday. Finally, StockNews.com cut Omeros from a “hold” rating to a “sell” rating in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Omeros presently has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.